Shares of Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $1.90 and traded as low as $1.76. Immutep shares last traded at $1.76, with a volume of 110,154 shares trading hands.
Immutep Stock Down 6.8 %
The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01. The stock's fifty day moving average is $1.88 and its two-hundred day moving average is $1.98.
Institutional Trading of Immutep
Hedge funds have recently bought and sold shares of the company. XY Capital Ltd raised its holdings in shares of Immutep by 52.0% during the fourth quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company's stock valued at $357,000 after acquiring an additional 56,306 shares during the period. ABC Arbitrage SA acquired a new stake in Immutep during the 4th quarter valued at $152,000. Two Sigma Securities LLC acquired a new stake in Immutep during the 4th quarter valued at $74,000. OLD Mission Capital LLC acquired a new stake in shares of Immutep in the fourth quarter worth $36,000. Finally, Fortitude Advisory Group L.L.C. acquired a new stake in shares of Immutep in the fourth quarter worth $28,000. 2.32% of the stock is owned by hedge funds and other institutional investors.
Immutep Company Profile
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Recommended Stories
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
